Compare ARK Genomic Revolution ETF (ARKG) vs Msci Inc (MSCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Msci Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Msci Inc trades at $606.2 (market cap $44.02B). The key difference: Msci Inc pays a 1.36% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Msci Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | MSCI | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $643.83 |
52-Week Low | $23.09 | $511.84 |
Market Cap | — | $44.02B |
Enterprise Value | — | $50.19B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
MSCI trades at $604.71, up 0.23% today, with a bullish technical signal and strong support at $595. The stock shows robust fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.74%, though valuations are elevated with a P/E of 34.54. Recent news highlights strategic partnerships with UBS and acquisitions to enhance its private markets and climate risk capabilities.
Outlook is positive given consistent earnings beats and a consensus price target of $718.14, but risks include high debt levels and reliance on market data demand. Analyst sentiment is strongly bullish with 73% buy ratings, supporting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
